Syncona has invested £34m ($43m) in start-up financing for Quell Therapeutics, a cell therapy company focusing on using T regulatory (Treg) cells to treat diseases of the immune system. The UK-based life sciences venture capital firm is launching Quell with the aim of developing Tregs therapies for solid organ transplant rejection, autoimmune and inflammatory diseases, with another £1m in funding coming from UCL Technology Fund. Source: PMLive 20/5/2019